Against the physician's credo "do no harm, " renal ischemia-reperfusion injury (IRI) stands as an anathema. As if the clinical burden from renal IRI secondary to other causes isn't enough, kidney transplant care teams everywhere face daily the irony that at some point, the patient's remedy, a kidney allograft , must fi rst suff er an unavoidable and troublesome insult: complete ischemia during transfer from the donor to the recipient, followed by reperfusion once vascular anastomosis in the recipient is complete. To counter the jeopardy this poses to kidney function in the recipient, investigators have worked diligently for years in clinical settings and in the laboratory to understand the pathophysiology of renal IRI and to devise ways to lessen its detriment to the allograft . Notwithstanding the great strides resulting from these eff orts, renal IRI continues to factor into delayed graft function, acute rejection, and chronic allograft nephropathy.
Along the cascade of pathogenic events that cause renal IRI, there has been an appreciation for the early innate immune response within the kidney itself and its role in priming the kidney for further injury. One puzzling question, however, has been which populations of cells resident within the kidney are most important in mediating this 'sterile' infl ammatory response. Th anks to a study by Dong 1 demonstrate that resident renal DCs are the predominant source of intrarenal tumor necrosis factor-α (TNF-α) in early renal IRI ( Figure 1 ).
Although other cytokines and chemokines produced by resident renal DCs probably play a role in the pathogenesis of renal IRI, the seemingly limited focus by Dong et al. on TNF-α 1 is well founded. Soluble TNF-α can be abundantly expressed by mononuclear phagocyte lineages (for example, myeloid DCs and macrophages), natural killer cells, and certain T-lymphocyte eff ectors (for example, T-helper 17 (Th17) and Th1 lymphocytes) and mediates its effects by engaging TNF receptor-1 (TNFR-1), which is normally present at basal levels on most quiescent cells, and TNFR-2, which is normally present on endothelial cells and some leukocytes. 3 Th is pleiotropic reservoir of TNF-α-responsive cell types explains TNF-α's harmful eff ects when its synthesis and release are poorly controlled. 3 During renal IRI in the allograft , for example, the substantial early production of TNF-α by resident renal DCs 1 and the subsequent activation of adjacent TNFRs could induce apoptosis of renal epithelium, 3 and, thus, the generation of alloantigen, all the while causing upregulation of adhesion molecules on renal endothelium, thereby promoting extravasation of the recipient's leukocytes into the allograft . Among several possibilities, the latter could include preexisting populations of T-lymphocyte eff ectors that further propagate renal IRI 4 or the recipient's own traffi cking DCs, ready to commentar y scavenge and present alloantigen. Indeed, increased levels of intrarenal TNF-α in early renal IRI have already been shown to strongly predict adverse outcomes for kidney allograft s. 5 Th e predominant production of TNF-α by resident renal DCs over other renal cells in early renal IRI 1 invokes the conundrum of how lipopolysaccharide (LPS) injures the kidney. LPS, a potent inducer of TNF-α secretion from DCs via the pattern recognition receptor (PRR) Toll-like receptor 4 (TLR4), can cause apoptosis of renal epithelium and acute renal failure (ARF). However, LPS can also engage TLR4 on other renal cell types, including renal epithelium. 6 Th e question has been, then, which specific TLR4 + renal cells might mediate LPS-induced ARF and how it occurs. Th is was recently addressed by Cunningham and colleagues, who studied the renal response to LPS aft er cross-transplantation of kidneys between normal mice and TNFR-1-null mice, 7 or between normal mice and mice with inactive TLR4. 8 Th ey discovered that TNFR-1-null kidneys placed in normal mice were protected from ARF caused by LPS, whereas normal kidneys placed in TNFR-1-null mice readily developed ARF. 7 In contrast, kidneys with inactive TLR4 developed LPS-induced ARF when placed in normal mice, whereas normal kidneys placed in mice with inactive TLR4 developed mild ARF that eventually recovered. 8 Together, these studies suggest that LPS does not directly injure renal epithelium via TLR4 but activates other intra-and extrarenal TLR4 + cell populations (for example, DCs) to produce TNF-α and damage renal epithelium via TNFR-1. Placing these studies on LPS-induced renal injury 7, 8 in the context of those by Dong et al. on renal IRI, 1 one might reasonably question whether TNF-α is ever produced by renal cells other than renal DCs early aft er an insult at levels suffi cient to cause autocrine-or paracrine-mediated injury via TNFR-1. Interestingly, TLR4 mediates IRI in the liver and in the heart. 6 If the same holds true in the kidney, then the study by Dong et al. 1 will be a primer for carefully exploring the TLR4 + renal DC compartment before assigning mechanisms of injury to other TLR4 + renal-cell compartments.
With resident renal DCs now identifi ed as major infl ammatory mediators in early renal IRI, 1 the possibility arises for direct targeting of renal DCs to help ameliorate renal IRI, particularly in allografts that could undergo pharmacologic preconditioning. For example, if resident renal DCs are stimulated to produce TNF-α by endogenous agonists of PRRs and not by some other intrinsic mechanism during renal IRI, then defi ning the repertoire of responsible PRRs would allow for the selection of appropriate PRR antagonists to block or attenuate the activation of renal DCs. 6 Alternatively, signal transduction pathways downstream of PRRs could be targeted. One recent study demonstrated the potency of GSK-3 inhibition in modulating the downstream signaling from PRRs in DCs in vivo, where proinfl ammatory responses were switched into tolerogenic, anti-infl ammatory responses (for example, secretion of interleukin-10) and mice were rendered completely resistant to the harmful eff ects of LPS. 9 Th is is intriguing because development of pharmacologic GSK-3 inhibitors is well under way for other renal diseases, 10 making them potentially attractive drugs for use in renal IRI as well. In summary, the surveying renal DC network is loudly sounding the alarm in renal IRI, and eff orts to target the renal DC compartment in the kidney may help to combat this common form of renal injury. 
